Has Coretta Collins received payments from drug or device companies?

Yes. Drug and device makers reported $77,013 in general payments to Coretta Collins across 497 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Coretta Collins did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Coretta Collins come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Coretta Collins

Acute Care · Birmingham, ALNPI 1104258532

Payments from drug & device makers

$77,013in general payments, 2019–2025

Across 497 payments — averaging $154.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$64K
Global Blood Therapeutics, Inc.$5K
Novartis$2K
Pfizer$2K
E.r. Squibb & Sons, L.L.C.$608
AbbVie$441
plus $4K from 39 others

What the payments were for

Consulting fees$4,2606%
Speaking & faculty fees$44,32558%
Travel & lodging$19,00225%
Food & beverage$8,22811%
Education$1000%
Other$1,0981%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	158	$64,224
Global Blood Therapeutics, Inc.	18	$4,759
Novartis	54	$1,743
Pfizer	26	$1,668
E.r. Squibb & Sons, L.L.C.	33	$608
AbbVie	14	$441
Amgen	20	$362
AstraZeneca(2 entities)	16	$361
Seagen Inc.	18	$299
Merck	13	$218
Gilead(2 entities)	12	$178
Sanofi	8	$168
Johnson & Johnson	8	$152
Incyte Corporation	8	$152
Beigene USA, Inc.	10	$145
Bristol Myers Squibb	8	$141
Pharmacosmos Therapeutics Inc.	1	$115
Eisai Inc.	5	$105
Jazz Pharmaceuticals Inc.	6	$103
Pharmacyclics LLC, An Abbvie Company	6	$99
Taiho Oncology, Inc.	4	$71
Blueprint Medicines Corporation	4	$67
Array Biopharma Inc	4	$66
Deciphera Pharmaceuticals Inc.	4	$62
Takeda Pharmaceuticals U.S.A., Inc.	3	$58
Bayer	3	$58
Daiichi Sankyo Inc.	2	$48
Puma Biotechnology, Inc.	3	$48
Karyopharm Therapeutics Inc.	3	$47
Morphosys, US Inc.	3	$46
Boston Scientific	2	$41
Ipsen Biopharmaceuticals, Inc	2	$41
Regeneron Healthcare Solutions, Inc.	2	$36
AMAG Pharmaceuticals, Inc.	2	$34
Acrotech Biopharma Inc.	2	$32
EMD Serono, Inc.	2	$32
Boehringer Ingelheim	1	$26
Astellas Pharma US Inc	2	$25
Melinta Therapeutics, LLC	1	$25
GSK	1	$21
Kyowa Kirin, Inc.	1	$19
Sanofi-aventis U.S. LLC	1	$19
Scilex Pharmaceuticals Inc.	1	$17
Sobi, Inc	1	$17
Myovant Sciences Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OXBRYTA$3,347
TALZENNA$1,260
Monoferric$115

How this compares

$77,013 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama →

Medicare billing

Part B allowed, 2024

$2,544

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Birmingham

Cameron StephensonBirmingham$13K
Jonathan McCraryBirmingham$13K
Michelle PriceBirmingham$13K
Melissa FrenchBirmingham$13K
Jaime CannonBirmingham$12K
Kaci WeaverBirmingham$11K
Alexandra GlennBirmingham$11K
Bridget CrainBirmingham$10K
Rachel CookBirmingham$10K
Kaitlyn JonesBirmingham$9K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →